Maravai Lifesciences Hits New 52-Week High of $6.21

Maravai Lifesciences Holdings, Inc. has reached a significant milestone by hitting a new 52-week high of USD 6.21 on June 25, 2026. This achievement marks a notable point for the small-cap company operating within the Pharmaceuticals & Biotechnology sector. Despite the recent uptick in stock price, Maravai's one-year performance reflects a decline of 27.4%, contrasting sharply with the S&P 500's gain of 20.77% over the same period. The company's market capitalization stands at USD 735 million, categorizing it as a micro-cap entity. Financial metrics indicate that Maravai is currently loss-making, with a return on equity of -43.31%. The company maintains a debt-to-equity ratio of 0.39, suggesting a moderate level of leverage. Additionally, the price-to-book ratio is reported at 3.46, while the dividend yield remains at 0.00%. The stock's previous 52-week low was recorded at USD 1.99, highlighting the significant recovery in its price trajectory. This recent performance underscores the dynamic nature of Maravai Lifesciences in the competitive biotechnology landscape.